Gene expression profiling and prediction of clinical outcome in ovarian cancer.
Epithelial ovarian cancer is the most lethal gynaecological cancer. Despite debulking surgery and platinum/taxane-based chemotherapy, the prognosis remains poor with approximately 25% 5-year survival. Current histo-clinical prognostic factors are insufficient to capture the complex cascade of events that drive the heterogeneous clinical behaviour of the disease. There is a crucial need to identify new prognostic subclasses of disease as well as new therapeutic targets. Today, DNA microarrays allow the simultaneous and quantitative analysis of the mRNA expression levels of thousands of genes in a tumour sample. They have been applied to ovarian cancer research for predicting initial surgical resectability, survival and response to first-line chemotherapy. The first results are promising. In this review, we describe recent applications of DNA microarrays in ovarian cancer research and discuss some issues to address in the near future to allow the technology to reach its full potential in clinical practice.
Sabatier
Renaud
R
Centre de Recherche en Cancérologie de Marseille (CRCM), Département d'Oncologie Moléculaire, UMR891 Inserm, Institut Paoli-Calmettes (IPC), IFR137 Marseille, France.
Finetti
Pascal
P
Cervera
Nathalie
N
Birnbaum
Daniel
D
Bertucci
François
F
D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D020411:Oligonucleotide Array Sequence Analysis; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000401:mortality; D011379:Prognosis